检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《现代预防医学》2007年第23期4459-4460,共2页Modern Preventive Medicine
摘 要:[目的]探讨HCV在特殊人群中的流行和干扰素治疗效果对HCV-RNA含量的影响。[方法]收集223份抗-HCV阳性血清并跟踪观察和用荧光定量实时荧光定量PCR法检测HCV-RNA的含量。[结果]在141份抗-HCV阳性血清中,58份实时荧光定量PCR阳性,阳性符合率为41.13%,在86份有输血史患者中39份实时荧光定量PCR阳性,阳性率为45.35%,17份有家族遗传史患者中11份实时荧光定量PCR阳性符合率为64.70%。在38例不明原因感染者中有8份实时荧光定量PCR阳性,阳性率为21.05%(2χ=16.21Р=0.000)。58例实时荧光定量PCR阳性的病人经治疗两年后,39份有输血史患者,转阴24例,转阴率61.53%。11份有家族遗传史患者中6例转阴,转阴率54.54%。在8例不明原因感染者中有5例转阴,转阴率62.24%。[结论]不同的传染途径在RNA的含量和治疗的预后有差异。[Objective]In order to research the prevalence of HCV in the special people and cured effects by interferon.[Methods]223 sera in which anti-HCV were positive were collected and observed,then used the real-time fluorescent quantitative PCR in detecting HCV-RNA.[Results]There were 58 HCV-RNA positive sera in 141 anti-HCV positive sera,the positive rate was 41.13%.There were 39 HCV-RNA positive sera in 86 sera which were from the patients with the history of blood transfusion,the positive rate was 26.82%.There were 11 HCV-RNA positive sera in17 sera which were from the patients with family heredity,the positive rate was 26.82%.There were 8 HCV-RNA positive sera in 38 sera which were from the infected patients with no remarkable reasons,the positive rate was 21.05%.There were remarkable differences among the groups(χ2 = 16.21,Р = 0.000).58 HCV-RNA positive patients in which 39 patients with the history of blood transfusion were treated with interferon,24 patients' sera became negative,the negative rate was 61.53%.The sera of 6 patients with family heredity became negative,the negative rate was 54.54%.The sera of 5 infected patients with no remarkable reasons became negative,the negative rate was 62.24%.[Conclusion]There are differences in the quantity of RNA and cured effects through different spread ways.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.90